# Phase 2 Lymphoma, Follicular trials recruiting: 62 (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 62 trials in phase 2 for Lymphoma, Follicular that are recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Recruiting Phase 2 Lymphoma, Follicular trials: 62 rows for $5, recruiting or not yet recruiting on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 1 row a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/recruiting/phase-2/lymphoma-follicular

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 62
- Recruiting or not yet: 62
- Read on: November 19, 2026

## Trials

The 25 newest of 62, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| October 23, 2026 | NCT07893197 | Ceritinib Treatment for Recurrent Meningiomas | Sponsor not shown (see the record) | Phase 2 | Not yet recruiting | Recurrent Meningioma, Grade I and Grade II | 10 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07893197) |
| October 22, 2026 | NCT07888647 | IDH1-vac in Patients With Newly Diagnosed IDH1R132H-positive High-grade Astrocytomas | German Cancer Research Center | Phase 2 | Not yet recruiting | Astrocytoma, IDH-Mutant, Grade 3, Astrocytoma, IDH-Mutant, Grade 4 | 216 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07888647) |
| October 15, 2026 | NCT07875413 | Prizloncabtagene Autoleucel (Prizlon-cel) for the Treatment of Relapsed or Refractory Large B-cell Lymphoma Post FDA Approved CAR T-cell... | AbelZeta Inc. | Phase 2 | Not yet recruiting | Large B Cell Lymphoma, LBCL, Diffuse Large B Cell Lymphoma (DLBCL), Relapse Diffuse Large B Cell Lymphoma, High Grade B... | 55 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07875413) |
| August 25, 2026 | NCT07783594 | Randomized Phase 2 Study Of Epcoritamab Vs Watch And Wait InPatients With Previously Untreated Low Tumor Burden FollicularLymphoma | M.D. Anderson Cancer Center | Phase 2 | Not yet recruiting | Randomized, Phase 2, Epcoritamab, Watch & Wait, Untreated, Tumor Burden, Follicular Lymphoma | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07783594) |
| July 28, 2026 | NCT07731789 | Tafasitamab and Rituximab for the Treatment of Newly Diagnosed Follicular Lymphoma | University of Washington | Phase 2 | Recruiting | Classic Follicular Lymphoma, Grade 1 Follicular Lymphoma, Grade 2 Follicular Lymphoma, Grade 3a Follicular Lymphoma | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07731789) |
| May 14, 2026 | NCT07585747 | A Exploratory Study on Untreated Follicular Lymphoma With Orelabrutinib, Tafasitamab, and Lenalidomide | Institute of Hematology & Blood Diseases Hospital, China | Phase 2 | Not yet recruiting | Follicular Lymphoma | 27 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07585747) |
| April 29, 2026 | NCT07555470 | Mosunetuzumab and Zeprumetostat in Treating Patients With Follicular Lymphoma | Institute of Hematology & Blood Diseases Hospital, China | Phase 2 | Recruiting | Follicular Lymphoma | 80 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07555470) |
| April 24, 2026 | NCT07550855 | Sonrotoclax, Zanubrutinib and Rituximab in Previously Untreated Patients With Follicular Lymphoma | Sun Yat-sen University | Phase 2 | Not yet recruiting | Follicular Lymphoma (FL) | 52 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07550855) |
| April 22, 2026 | NCT07545603 | Clinical Study of XNW5004 Tablets in the Treatment of Relapsed and Refractory Follicular Lymphoma | Evopoint Biosciences Inc. | Phase 2 | Recruiting | Follicular Lymphoma, Grade 1, Follicular Lymphoma, Grade 2, Follicular Lymphoma, Grade 3, Follicular Lymphoma Grade 3A | 65 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07545603) |
| April 1, 2026 | NCT07505849 | ZR2 Versus R2 Regimen in the Treatment of Newly Diagnosed Follicular Lymphoma | Sponsor not shown (see the record) | Phase 2 | Not yet recruiting | Follicular Lymphomas | 100 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07505849) |
| February 18, 2026 | NCT07418190 | Efficacy and Safety of Zanubrutinib, Rituximab, and Lenalidomide (ZR²) in Combination With Tislelizumab for Relapsed/Refractory Follicular... | The First Affiliated Hospital with Nanjing Medical University | Phase 2 | Recruiting | Relapsed/Refractory Follicular Lymphoma | 33 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07418190) |
| January 22, 2026 | NCT07360288 | Efficacy and Safety of TC011 in Relapsed or Refractory Follicular Lymphoma | TICAROS Co., Ltd. | Phase 2 | Not yet recruiting | Follicular Lymphoma (FL) | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07360288) |
| December 23, 2025 | NCT07299149 | Zanubrutinib, Obinutuzumab Combined With Lenalidomide (ZGR) for the Treatment of Untreated Follicular Lymphoma | Institute of Hematology & Blood Diseases Hospital, China | Phase 2 | Recruiting | Follicular Lymphoma | 34 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07299149) |
| September 29, 2025 | NCT07197307 | Combining Loncastuximab Tesirine and Epcoritamab in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) | Universität Münster | Phase 2 | Recruiting | Aggressive Diffuse Large B-cell Lymphoma, High-grade B-cell Lymphoma (HGBL), Follicular Lymphoma (FL) Grade 3B | 120 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07197307) |
| September 24, 2025 | NCT07191249 | Trial to Evaluate Efficacy and Safety of Subcutaneous Mosunetuzumab in Previously Untreated Low Tumor Burden Follicular Lymphoma . | Tel-Aviv Sourasky Medical Center | Phase 2 | Recruiting | Follicular Lymphoma | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07191249) |
| August 19, 2025 | NCT07128641 | Odronextamab in Low Tumor Volume Advanced FL | Sponsor not shown (see the record) | Phase 2 | Recruiting | Follicular Lymphoma, Lymphoma | 35 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07128641) |
| July 22, 2025 | NCT07077512 | Relmacabtagene Autoleucel Combined With Sintilimab for Relapsed/Refractory B-cell Lymphoma | Sun Yat-sen University | Phase 2 | Recruiting | Large B Cell Diffuse Lymphoma, Mantle Cell Lymphoma (MCL), Follicular Lymphoma ( FL) | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07077512) |
| June 22, 2025 | NCT07031700 | A Multicenter, Single-Arm, Open-Label, Phase II Trial of Mosunetuzumab in Combination With Tislelizumab for r/r FL | Tianjin Medical University Cancer Institute and Hospital | Phase 2 | Not yet recruiting | Relapsed/Refractory Follicular Lymphoma | 22 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07031700) |
| June 19, 2025 | NCT07029503 | Swedish Cardiac And Renal Failure Study-1 | Karolinska Institutet | Phase 2 | Recruiting | HFrEF - Heart Failure With Reduced Ejection Fraction, Chronic Kidney Disease | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07029503) |
| May 7, 2025 | NCT06959732 | Zanubrutinib Combined With G-CVP in Previously Untreated FL | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Phase 2 | Recruiting | Follicular Lymphoma ( FL) | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06959732) |
| April 29, 2025 | NCT06948786 | Pirtobrutinib and Mosunetuzumab for the Treatment of Relapsed/Refractory Grades 1-3A Follicular Lymphoma, PROMOTE-FL Trial | University of Washington | Phase 2 | Recruiting | Grade 1 Follicular Lymphoma, Grade 2 Follicular Lymphoma, Grade 3a Follicular Lymphoma, Recurrent Follicular Lymphoma... | 22 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06948786) |
| April 9, 2025 | NCT06918015 | Zanubrutinib Plus GCVP (Obinutuzumab, Cyclophosphamide, Vindesine, Prednisolone) in Previously Untreated Follicular Lymphoma | Zhejiang Cancer Hospital | Phase 2 | Not yet recruiting | BTK Inhibitors, Follicular Lymphoma, Immunochemotherapy | 58 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06918015) |
| February 28, 2025 | NCT06852638 | CD70-targeted immunoPET Imaging of Malignant Cancers | RenJi Hospital | Phase 2 | Recruiting | Renal Cancer, Renal Clear Cell Carcinoma, Lymphoma, Lymphoma, Large B-Cell, Diffuse, Follicular Lymphoma, Mantle Cell... | 300 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06852638) |
| February 13, 2025 | NCT06826118 | Axicabtagene Ciloleucel Injection in Patients With Relapsed/Refractory Follicular Lymphoma | The First Affiliated Hospital of Xiamen University | Phase 2 | Recruiting | Lymphoma, Follicular Lymphoma, Refractory Lymphoma | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06826118) |
| January 27, 2025 | NCT06792825 | HM2023-43:Ph 2 Trial of Tafasitamab With Lenalidomide+Rituximab in Treatment-naive FL and MZL | Masonic Cancer Center, University of Minnesota | Phase 2 | Recruiting | Follicular Lymphoma, Marginal Zone Lymphoma | 65 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06792825) |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| The First Affiliated Hospital of Xiamen University | 4 |
| Masonic Cancer Center, University of Minnesota | 4 |
| Sun Yat-sen University | 4 |
| Institute of Hematology & Blood Diseases Hospital, China | 3 |
| University of Washington | 3 |
| M.D. Anderson Cancer Center | 3 |
| Tianjin Medical University Cancer Institute and Hospital | 2 |
| H. Lee Moffitt Cancer Center and Research Institute | 1 |
| Karolinska Institutet | 1 |
| German Cancer Research Center | 1 |
| Australasian Leukaemia and Lymphoma Group | 1 |
| Fred Hutchinson Cancer Center | 1 |
| Neonc Technologies, Inc. | 1 |
| Oslo University Hospital | 1 |
| University of Birmingham | 1 |
| [AstraZeneca](https://specstream.ai/data/clinical-trials/company/astrazeneca) | 1 |
| AbelZeta Inc. | 1 |
| [Jiangsu HengRui Medicine Co., Ltd.](https://specstream.ai/data/clinical-trials/company/jiangsu-hengrui-medicine-co-ltd) | 1 |
| [Evopoint Biosciences Inc.](https://specstream.ai/data/clinical-trials/company/evopoint-biosciences-inc) | 1 |
| Beth Israel Deaconess Medical Center | 1 |
| Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 1 |
| Indiana University | 1 |
| Tel-Aviv Sourasky Medical Center | 1 |
| Hope Biosciences LLC | 1 |
| Chinese PLA General Hospital | 1 |

## By country

| Country | Trials |
| --- | --- |
| United States | 30 |
| China | 21 |
| Germany | 3 |
| Sweden | 2 |
| Australia | 2 |
| Norway | 2 |
| United Kingdom | 2 |
| Canada | 2 |
| Finland | 1 |
| Brazil | 1 |
| Denmark | 1 |
| France | 1 |
| Hong Kong | 1 |
| Italy | 1 |
| Japan | 1 |
| South Korea | 1 |
| Spain | 1 |
| Taiwan | 1 |
| Israel | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Sign makers in the United States](https://specstream.ai/data/businesses/sign-makers/united-states)
- [Antenna companies in the United States](https://specstream.ai/data/businesses/antenna-companies/united-states)
- [Commercial printers in the United States](https://specstream.ai/data/businesses/commercial-printers/united-states)
- [Gerontology practices in the United States](https://specstream.ai/data/businesses/gerontology-practices/united-states)
- [Moroccan restaurants in the United States](https://specstream.ai/data/businesses/moroccan-restaurants/united-states)
- [Senegalese restaurants in the United States](https://specstream.ai/data/businesses/senegalese-restaurants/united-states)
